Business Context and Reporting Period
This Form 8-K, dated June 30, 2011, reports a material acquisition and corporate restructuring by VistaGen Therapeutics, Inc. (formerly Excaliber Enterprises, Ltd.). On May 11, 2011, the Company acquired all outstanding shares of VistaGen Therapeutics, Inc. (California) in exchange for 6,836,452 shares of the Company's Common Stock. Following the acquisition, the Company adopted VistaGen Therapeutics' business operations. On May 23, 2011, the Board approved a name change to "VistaGen Therapeutics, Inc." and a 2-for-1 forward stock split, both effective on the OTC Bulletin Board on June 10, 2011.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or margin data. Key capital structure metrics as of the report date include:
- Outstanding Common Stock: 15,241,904 shares (post 2-for-1 split).
- Convertible Promissory Notes: One outstanding note totaling $4,686,548 (principal plus accrued interest).
- Preferred Stock: None outstanding (all converted during the acquisition).
- Options: 4,719,150 shares outstanding with a weighted average exercise price of $1.47.
- Warrants: 6,540,314 shares outstanding with a weighted average exercise price of $2.18.
Material Changes Versus Prior Period
The Company underwent a complete transformation of its business and capital structure:
- Business Shift: Transitioned from Excaliber Enterprises to the biopharmaceutical business of VistaGen Therapeutics.
- Debt Conversion: Prior to the acquisition, VistaGen held $10,805,780 in convertible notes. $6,174,787 of this debt was converted into Company Common Stock at closing. The remaining $4,686,548 remains outstanding.
- Equity Conversion: All 2,884,655 shares of VistaGen Preferred Stock were converted into Company Common Stock.
- Share Count: Pre-split outstanding shares were 7,620,952; post-split shares are 15,241,904.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future performance. The primary risk disclosed is the significant dilution of existing shareholders due to the issuance of 6,836,452 shares for the acquisition and the subsequent 2-for-1 stock split. Additionally, the Company carries a remaining debt obligation of approximately $4.7 million in convertible notes.
Investor Verification Checklist
- Verify the terms and maturity date of the remaining $4,686,548 convertible promissory note.
- Confirm the weighted average exercise prices of outstanding options ($1.47) and warrants ($2.18) relative to the current market price.
- Review the full list of Directors and Executive Officers, noting that the group collectively holds 24.30% of the class.
- Confirm the effective date of the name change and stock split on the OTC Bulletin Board (June 10, 2011).